Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive long-term psoriasis data for Cosentyx

Novartis reports positive long-term psoriasis data for Cosentyx

4th October 2016

Novartis has announced new clinical trial data demonstrating the long-term benefits its drug Cosentyx can offer for psoriasis patients.

Data presented at the annual European Academy of Dermatology and Venereology Congress has shown that Cosentyx can deliver high and long-lasting skin clearance in patients with moderate to severe plaque psoriasis over four years of treatment.

Clear or almost clear skin was achieved by 68.5 percent of patients at year one, with this high rate maintained to year four. Additionally, 43.8 percent of patients achieved completely clear skin after one year, with this performance shown to be sustained as well.

Also presented at the congress was data showing the longer-term efficacy of Cosentyx in treating psoriasis of the hands and feet, which are considered difficult areas to treat on the body.

Vasant Narasimhan, global head of drug development and chief medical officer at Novartis, said: "Psoriasis patients need therapies they can use over long periods of time without loss of efficacy and we are pleased that Cosentyx is proving a sustainable choice for patients."

Cosentyx is approved in more than 65 countries for the treatment of moderate to severe plaque psoriasis, as well as for ankylosing spondylitis and psoriatic arthritis in more than 50 territories.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826263-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.